MAPK/ERK pathway
From Proteopedia
(Difference between revisions)
Line 48: | Line 48: | ||
====MAPK phosphorylates and activates MNK, which, in turn, phosphorylates CREB. The activated CREB protein then binds to a CRE region, and is then bound to by CBP ([[CREB-binding protein]]), which coactivates it, allowing it to switch certain genes on or off. CBP is a transcription activator.==== | ====MAPK phosphorylates and activates MNK, which, in turn, phosphorylates CREB. The activated CREB protein then binds to a CRE region, and is then bound to by CBP ([[CREB-binding protein]]), which coactivates it, allowing it to switch certain genes on or off. CBP is a transcription activator.==== | ||
Genes whose transcription is regulated by CREB include: ''c-fos'', BDNF, tyrosine hydroxylase, numerous neuropeptides (such as somatostatin, enkephalin, VGF, corticotropin-releasing hormone),[2] and genes involved in the mammalian circadian clock (PER1, PER2). | Genes whose transcription is regulated by CREB include: ''c-fos'', BDNF, tyrosine hydroxylase, numerous neuropeptides (such as somatostatin, enkephalin, VGF, corticotropin-releasing hormone),[2] and genes involved in the mammalian circadian clock (PER1, PER2). | ||
+ | |||
+ | Genes whose transcription is regulated by CREB include: ''[[c-fos]]'', [[BDNF]], [[tyrosine hydroxylase]], numerous [[neuropeptide]]s (such as [[somatostatin]], [[enkephalin]], [[VGF]], [[corticotropin-releasing hormone]]),<ref name="Purves" /> and genes involved in the mammalian [[circadian clock]] ([[PER1]], [[PER2]]).<ref name=":0">{{Cite journal|title = The Mammalian Circadian Timing System: Organization and Coordination of Central and Peripheral Clocks|journal = Annual Review of Physiology|date = 2010|pmid = 20148687|pages = 517–549|volume = 72|issue = 1|doi = 10.1146/annurev-physiol-021909-135821|first1 = Charna|last1 = Dibner|first2 = Ueli|last2 = Schibler|first3 = Urs|last3 = Albrecht|url = http://doc.rero.ch/record/17505/files/alb_mct.pdf}}</ref> | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 14:48, 20 February 2022
|
References
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
- ↑ Cite error: Invalid
<ref>
tag; no text was provided for refs namedPurves
- ↑ <ref>PMID:9556453</ref>